Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and surgery. 25 patients will be recruited from approximately 15 NHS secondary care sites.

Trial Details

NCT ID
NCT05965479
Phase
PHASE2
Sponsor
University of Southampton
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Trastuzumab deruxtecan
Locations (sample)
  • Guildford, Surrey, United Kingdom|51.23536,-0.57427
  • Coventry, Warwickshire, United Kingdom|52.40656,-1.51217
  • Belfast, United Kingdom|54.59682,-5.92541
  • Cambridge, United Kingdom|52.2,0.11667
  • Derby, United Kingdom|52.92277,-1.47663

Key Eligibility Criteria

  • Pathologically documented adenocarcinoma of the stomach (clinical stage before surgery of AJCC I-III), gastroesophageal junction, or lower oesophag…
  • ctDNA positive after surgery as per Signatera assay
  • Capable of giving signed informed consent prior to any mandatory study specific procedures, sampling, or analyses and which includes compliance wit…
  • Male and female participants must be at least 18 years of age at the time of signing the ICF.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →